Companion Diagnostics Market Size, Share & Forecast

Name: Companion Diagnostics Market by Products (Assays, Kits & Reagents, Software & Services), by Technology (Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry), by Indication (Cancer, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases), by End User (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, Laboratories), and Region, Global trends and forecast from 2022 to 2029
Price: 3499 USD
Availability: InStock
Rating: 4.5 (94 reviews)
Author: Exactitude Consultancy
ISBN: 14558

Companion Diagnostics Market Overview

The Companion Diagnostics Market Is Expected To Grow At 13.34% CAGR From 2021 To 2029. It Is Expected To Reach Above USD 13.23 Billion By 2029 From USD 3.5 Billion In 2020.

Companion diagnostics are in-vitro tests that provide information about patients' therapeutic responses to a specific treatment. It is an in vitro medical device that provides information necessary for the safe and effective management of a corresponding drug or biological product. This diagnostic test assists a physician in determining whether a specific therapeutic product is beneficial to patients and can outweigh any potential serious side effects or risks.

The increase in various types of cancer among people is primarily driving market growth. As the number of clinical trials increases and the demand for next-generation sequencing grows, so will the growth of the companion diagnostic market. Another factor driving such growth is the importance of this market's products in the production of various types of drugs.

The companion diagnostics market is expected to grow significantly during the forecast period, owing to an increase in R&D of targeted therapies, an increase in demand for precision medicine with rising attention in emerging economies, the discovery of new biomarkers for various conditions, and a higher number of unmet needs for cancer treatment.

With signs of progress in hereditary sequencing and genomics, it is now widely accepted that medications can generate varying results in different people. A superior understanding of an individual's hereditary characteristics or biomarkers can advance the act of overseeing 'the right medication, with impeccable timing, at the right portion, for the perfect individual'. Drug and biopharmaceutical companies are constantly working to implement patient-choice analytic systems in the early stages of medication development in order to provide targeted treatments to the right competitor. This contributes to the growth of the companion diagnostics market.

ATTRIBUTE	DETAILS
Study period	2020-2029
Base year	2022
Estimated year	2022
Forecasted year	2022-2029
Historical period	2018-2020
Unit	Value (USD Billion)
Segmentation	By Offering, By Technology, By Indication, By End User, By Region
By Resin Technology	Assays, Kits & Reagents Software & Services
By Technology	Polymerase Chain Reaction Next-Generation Sequencing In Situ Hybridization Immunohistochemistry
By Indication	Cancer Neurological Diseases Infectious Diseases Cardiovascular Diseases
By End User	Pharmaceutical & Biopharmaceutical Companies Contract Research Organizations Laboratories
By Region	North America Asia Pacific Europe South America Middle East Asia & Africa

The introduction of COVID-19 has hampered consumption for companion diagnostics. In addition, key market players saw a significant drop in revenue as a result of the COVID-19 pandemic, owing to a reduction in testing volume and other factors. In regards to revenue, the market grew by 15.1% in 2020, compared to 19.8% in 2019.

Revenue generated by the major players decreased significantly in 2020. For example, Myriad Genetics, Inc. reported a 34.5% decrease in molecular diagnostics revenue in 2020 compared to 2019. In addition, Abbott Laboratories reported a 4.0% decrease in revenue from core laboratory diagnostics in 2020 compared to 2019.

However, the lifting of lockdown restrictions, stay-at-home orders in many countries, the introduction of novel diagnostic tests, and the re-establishment of the supply chain network were key factors in the recovery of testing in 2021. As a result, the resumption of cancer diagnostics testing and the introduction of new diagnostic tests boosted demand in 2021.

[caption id="attachment_14559" align="aligncenter" width="1024"]

Companion Diagnostics Market | Exactitude Consultancy[/caption]

Frequently Asked Questions

• What is the worth of companion diagnostics market?

The companion diagnostics market size had crossed USD 3.5 Billion in 2020 and will observe a CAGR of more than 13.34% up to 2029.

• What are some of the market's driving forces?

Major factors driving the companion diagnostics market growth include the significant growth of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

• Which are the top companies to hold the market share in companion diagnostics market?

Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major companion diagnostics market players.

• Which is the largest regional market for companion diagnostics market?

The region's largest share is in North America. Products manufactured in nations like US and Canada that perform similarly and are inexpensively accessible to the general public have led to the increasing appeal.

Companion Diagnostics Market Segment Analysis

The companion diagnostics market is segmented based on products, technology, indication, end user, and region, global trends and forecast.

On the basis of products, the market is segmented into assays, kits & reagents, software & services. Due to increase in demand for kits and reagents, the assays, kits and reagents segment is estimated to lead.

On the basis of technology, the market is segmented into polymerase chain reaction, next-generation sequencing, in situ hybridization, immunohistochemistry.

Based on technology, the pcr segment currently dominates the global market and is expected to do so throughout the forecast period. Cost effectiveness, high sensitivity, and specificity, which can be used for simple automated platforms, are some key factors driving market growth. Furthermore, the pcr, which is another key driver of this segment, can determine the sequencing of unknown etiologies of many diseases. However, the next generation sequencing segment is expected to grow rapidly during the forecast period due to key advantages such as higher sensitivity to detect low-frequency variants, shorter turnaround time for large sample volumes, the ability to sequence hundreds to thousands of genes or gene regions simultaneously, and so on.

On the basis of indication, the market is segmented into cancer, neurological diseases, infectious diseases, cardiovascular diseases.

The cancer segment is currently the largest revenue generator and is expected to grow significantly during the forecast period. Some key factors driving the growth of the cancer segment include increased cancer prevalence, increased r&d activities for cancer, increased unmet needs for cancer treatment, increased number of fda approved companion diagnostics, and increased patient awareness of personalized medicine.

Cancer research has discovered significant differences in gene sequence and expression patterns that can serve as the foundation for targeted therapy. Furthermore, many biomarkers for various cancers have been identified, for which companion diagnostics have been developed. Companion diagnostics are widely used in various types of cancer, including lung cancer, colorectal cancer, breast cancer, and blood cancer, which are the leading causes of death.

On the basis of end user, the market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, laboratories.

There is no denying that contract research organizations (cros) are becoming more important in the development of companion diagnostics. As the demand for personalized medicine grows, cros are uniquely positioned to assist pharmaceutical and biotechnology companies in developing customized treatments based on a patient's unique genetic makeup.

Companion diagnostics are diagnostic tests used to identify patients who are likely to benefit from a specific treatment. They can also be used to track a patient's response to therapy and make necessary adjustments. Cancer, cardiovascular disease, and infectious diseases are just a few of the conditions that can be treated with companion diagnostics.

[caption id="attachment_14563" align="aligncenter" width="1920"]

Companion Diagnostics Market | Exactitude Consultancy[/caption]

Companion Diagnostics Market Players

Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major Companion Diagnostics market players. Recent Developments: 23 January, 2023: QIAGEN Digital Insights announced launch of their enhanced QIAGEN CLC Genomics Workbench Premium that removes the data-analysis bottleneck of Next-Generation Sequencing by adding analysis speed to analyze and interpret Whole Genome Sequencing, Whole Exome Sequencing and Large Panel Sequencing data. 9 January, 2023: QIAGEN announced of having been completed the acquisition of Verogen, a leader in the use of Next-Generation Sequencing technologies to drive the future of human identification and forensic investigation.

Who Should Buy? Or Key stakeholders

Pharmaceutical Companies
Research and Development (R&D) Companies
Diagnostic Laboratories
Government Research Institute
Academic Institutes and Universities
Investors
Regulatory Authorities

Companion Diagnostics Market Regional Analysis

The Companion Diagnostics Market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).

North America: includes the US, Canada, Mexico
Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
South America: includes Brazil, Argentina and Rest of South America
Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA

North America is expected to lead the global companion diagnostics market. This could explain the high incidence rate of cancer and other chronic diseases, as well as the rising cost of healthcare in the area. Furthermore, market development is expected to drive an increase in the number of healthcare organisations working on generated genomic databases to better understand the human genome, as well as increased research activities in this area using companion diagnostic kits.

The European market for companion diagnostics is expected to be the second-largest during the review period. The expansion of the regional industry is expected to fuel the participation of a large number of companies as well as increased research and development activities aimed at improving personalised drug treatment for cancer patients. Furthermore, rising per capita income increases the preference for personalised treatment, fueling further consumer growth.

Because of the rapidly increasing number of cancer, cardiovascular, and neurological patients, Asia-Pacific is expected to be the fastest growing region. Furthermore, the rising prevalence of infectious diseases has a positive impact on business development. The high prevalence of cancer, increasing proteomics and genomics research, rising research funding, increasing investments by pharmaceutical and biotechnology firms, and rising awareness of personalised therapeutics in many APAC countries are expected to drive the growth of the APAC companion diagnostics market.

The Middle East and Africa market is expected to grow steadily due to an increase in cancer cases and a growing preference for customised drugs. The Middle East and Africa market is expected to grow steadily due to an increase in the number of hospitals and research labs, increased investment by healthcare firms, an increase in cancer cases, and increased drug discovery.

[caption id="attachment_14564" align="aligncenter" width="1920"]

Companion Diagnostics Market | Exactitude Consultancy[/caption]

Key Market Segments: Companion Diagnostics Market

Companion Diagnostics Market By Offering 2020-2029, (Usd Billion)
Assays, Kits & Reagents
Software & Services

Companion Diagnostics Market By Technology, 2020-2029, (Usd Billion)

Polymerase Chain Reaction
Next-Generation Sequencing
In Situ Hybridization
Immunohistochemistry

Companion Diagnostics Market By Indication, 2020-2029, (Usd Billion)

Cancer
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases

Companion Diagnostics Market By End User, 2020-2029, (Usd Billion)

Pharmaceutical & Biopharmaceutical Companies
Contract Research Organizations
Laboratories

Companion Diagnostics Market By Region, 2020-2029, (Usd Billion)

North America
Asia Pacific
Europe
South America
Middle East And Africa

Important Countries In All Regions Are Covered.

Exactitude Consultancy Core Companion Diagnostics Services Key Objectives:

Increasing sales and market share
Developing new technology
Improving profitability
Entering new markets
Enhancing brand reputation

Key Question Answered

What is the expected growth rate of the companion diagnostics market over the next 7 years?
Who are the major players in the companion diagnostics market and what is their market share?
What are the end-user industries driving demand for market and what is their outlook?
What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
How is the economic environment affecting the companion diagnostics market, including factors such as interest rates, inflation, and exchange rates?
What is the expected impact of government policies and regulations on the companion diagnostics market?
What is the current and forecasted size and growth rate of the global companion diagnostics market?
What are the key drivers of growth in the companion diagnostics market?
What are the distribution channels and supply chain dynamics in the companion diagnostics market?
What are the technological advancements and innovations in the companion diagnostics market and their impact on product development and growth?
What are the regulatory considerations and their impact on the market?
What are the challenges faced by players in the companion diagnostics market and how are they addressing these challenges?
What are the opportunities for growth and expansion in the companion diagnostics market?
What are the service offerings and specifications of leading players in the market?

INTRODUCTION
1. MARKET DEFINITION
2. MARKET SEGMENTATION
3. RESEARCH TIMELINES
4. ASSUMPTIONS AND LIMITATIONS

RESEARCH METHODOLOGY
1. DATA MINING
  1. SECONDARY RESEARCH
  2. PRIMARY RESEARCH
  3. SUBJECT-MATTER EXPERTS’ ADVICE
2. QUALITY CHECKS
  1. FINAL REVIEW
3. DATA TRIANGULATION
  1. BOTTOM-UP APPROACH
  2. TOP-DOWN APPROACH
  3. RESEARCH FLOW
4. DATA SOURCES

EXECUTIVE SUMMARY

MARKET OVERVIEW
1. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK
  1. MARKET DRIVERS
  2. MARKET RESTRAINTS
  3. MARKET OPPORTUNITIES
2. IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
3. PORTER’S FIVE FORCES MODEL
  1. THREAT FROM NEW ENTRANTS
  2. THREAT FROM SUBSTITUTES
  3. BARGAINING POWER OF SUPPLIERS
  4. BARGAINING POWER OF CUSTOMERS
  5. DEGREE OF COMPETITION
4. INDUSTRY VALUE CHAIN ANALYSIS

GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION), 2020-2029
1. ASSAYS, KITS & REAGENTS
2. SOFTWARE & SERVICES
3. CORE COMPANION DIAGNOSTICS SERVICES

GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION), 2020-2029
1. POLYMERASE CHAIN REACTION
2. NEXT-GENERATION SEQUENCING
3. IN SITU HYBRIDIZATION
4. IMMUNOHISTOCHEMISTRY

GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION), 2020-2029
1. CANCER
2. NEUROLOGICAL DISEASES
3. INFECTIOUS DISEASES
4. CARDIOVASCULAR DISEASES

GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION), 2020-2029
1. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
2. CONTRACT RESEARCH ORGANIZATIONS
3. LABORATORIES

GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION), 2020-2029
1. NORTH AMERICA
  1. US
  2. CANADA
  3. MEXICO
2. SOUTH AMERICA
  1. BRAZIL
  2. ARGENTINA
  3. COLOMBIA
  4. REST OF SOUTH AMERICA
3. EUROPE
  1. GERMANY
  2. UK
  3. FRANCE
  4. ITALY
  5. SPAIN
  6. RUSSIA
  7. REST OF EUROPE
4. ASIA PACIFIC
  1. INDIA
  2. CHINA
  3. JAPAN
  4. SOUTH KOREA
  5. AUSTRALIA
  6. SOUTH-EAST ASIA
  7. REST OF ASIA PACIFIC
5. MIDDLE EAST AND AFRICA
  1. UAE
  2. SAUDI ARABIA
  3. SOUTH AFRICA
  4. REST OF MIDDLE EAST AND AFRICA

COMPANY PROFILES* (BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)
1. QIAGEN
2. AGILENT TECHNOLOGIES
3. ROCHE
4. ABBOTT LABORATORIES, INC.
5. BIOMERIEUX
6. VENTANA MEDICAL SYSTEMS
7. MYRIAD GENETICS, INC.
8. RESONANCE HEALTH LTD
9. LEICA MICROSYSTEMS
10. LIFE TECHNOLOGIES
11. HOFFMANN-LA ROCHE LTD.
12. ILLUMINA, INC.
13. GUARDANT HEALTH
14. THERMO FISHER SCIENTIFIC INC.
15. DANAHER CORPORATION *THE COMPANY LIST IS INDICATIVE

LIST OF TABLES

TABLE 1        GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 2        GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 3        GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 4        GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 5        GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION) 2020-2029

TABLE 6        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 7        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 8        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 9        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 10      NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 11      US COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 12      US COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 13      US COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 14      US COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 15      CANADA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 16      CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 17      CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 18      CANADA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 19      MEXICO COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 20      MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 21      MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 22      MEXICO COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 23      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 24      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 25      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 26      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 27      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 28      BRAZIL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 29      BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 30      BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 31      BRAZIL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 32      ARGENTINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 33      ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 34      ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 35      ARGENTINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 36      COLOMBIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 37      COLOMBIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 38      COLOMBIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 39      COLOMBIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 40      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 41      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 42      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 43      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 44      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 45      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 46      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 47      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 48      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 49      INDIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 50      INDIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 51      INDIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 52      INDIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 53      CHINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 54      CHINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 55      CHINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 56      CHINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 57      JAPAN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 58      JAPAN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 59      JAPAN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 60      JAPAN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 61      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 62      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 63      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 64      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 65      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 66      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 67      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 68      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 69      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 70      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 71      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 72      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 73      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 74      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 75      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 76      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 77      EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 78      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 79      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 80      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 81      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 82      GERMANY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 83      GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 84      GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 85      GERMANY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 86      UK COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 87      UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 88      UK COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 89      UK COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 90      FRANCE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 91      FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 92      FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 93      FRANCE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 94      ITALY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 95      ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 96      ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 97      ITALY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 98      SPAIN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 99      SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 100    SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 101    SPAIN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 102    RUSSIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 103    RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 104    RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 105    RUSSIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 106    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 107    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 108    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 109    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 110    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 111    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 112    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 113    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 114    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 115    UAE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 116    UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 117    UAE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 118    UAE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 119    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 120    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 121    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 122    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 123    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 124    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 125    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 126    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 127    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 128    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 129    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 130    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

LIST OF FIGURES

FIGURE 1 MARKET DYNAMICS

FIGURE 2 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 3 BOTTOM-UP APPROACH

FIGURE 4 RESEARCH FLOW

FIGURE 5 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING USD BILLION, 2020-2029

FIGURE 6 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2020-2029

FIGURE 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2020-2029

FIGURE 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2020-2029

FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2020-2029

FIGURE 10 PORTER’S FIVE FORCES MODEL

FIGURE 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING, USD BILLION, 2021

FIGURE 12 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2021

FIGURE 13 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2021

FIGURE 14 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2021

FIGURE 15 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2021

FIGURE 16 MARKET SHARE ANALYSIS

FIGURE 17 QIAGEN: COMPANY SNAPSHOT

FIGURE 18 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 19 ROCHE: COMPANY SNAPSHOT

FIGURE 20 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT

FIGURE 21 BIOMERIEUX: COMPANY SNAPSHOT

FIGURE 22 VENTANA MEDICAL SYSTEMS: COMPANY SNAPSHOT

FIGURE 23 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT

FIGURE 24 RESONANCE HEALTH LTD: COMPANY SNAPSHOT

FIGURE 25 LEICA MICROSYSTEMS: COMPANY SNAPSHOT

FIGURE 26 LIFE TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 27 F. HOFFMANN-L ROCHE LTD.: COMPANY SNAPSHOT

FIGURE 28 ILLUMINA, INC.: COMPANY SNAPSHOT

FIGURE 29 GUARDANT HEALTH: COMPANY SNAPSHOT

FIGURE 30 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT

Identifying Key Products in the Market

The identification of key products in any market is pivotal for understanding what drives consumer interest, technological innovation, and competitive advantage. Here’s how to approach this:
Market Analysis Reports: Start with syndicated market analysis reports from firms like Nielsen, Euromonitor, or specialized industry analysts. These reports often highlight leading products based on sales data, innovation, and consumer feedback.
Patent Filings: Reviewing patent filings can provide insight into technological innovations and future products that may impact the market. Databases like the United States Patent and Trademark Office (USPTO) or the World Intellectual Property Organization (WIPO) can be invaluable.
Ecommerce Platforms and Retailer Websites: Analyzing bestselling products and customer reviews on platforms such as Amazon, Flipkart, or direct retailer websites can offer direct insights into consumer preferences and product popularity.
Consumer Surveys and Feedback: Conducting surveys or analyzing online forums and social media can reveal consumer preferences, pain points, and desired features in products. Tools like SurveyMonkey, Google Surveys, or social listening platforms can facilitate this process.

Segmenting the Market and Products

Market and product segmentation is crucial for targeting marketing efforts and product development. Here’s a methodology for segmenting based on technical specifications:
Technical Specifications Review: Compile a comprehensive list of products within the market, focusing on their technical specifications. This could involve processor speeds for electronics, ingredients for food products, or material composition for apparel.
Factor Analysis: Use statistical techniques like factor analysis to group products based on shared technical specifications. This method helps identify underlying relationships between different specifications and how they cluster together.
Expert Consultation: Engage with industry experts or technical specialists to ensure that the segmentation makes sense from both a market and a technical perspective. This step ensures the practical relevance of the segments identified.

Identifying and Classifying Key Application Segments

Understanding how products are used in different applications is essential for market strategy:
Use Case Analysis: Identify common use cases for products by reviewing product literature, customer testimonials, and case studies. This helps understand the variety of applications each product serves.
Industry Surveys: Conduct surveys targeting professionals in the field to understand how and why certain products are preferred in specific applications. This can also reveal unmet needs in the market.
ApplicationBased Segmentation: Group products based on their primary applications, considering factors such as industry use, consumer vs. professional use, and environmental conditions.

Calculating Market Size Using TopDown and BottomUp Approaches

Estimating the market size accurately is fundamental for strategic planning:
TopDown Approach: Start with global industry data and narrow down to the target market by applying known market shares or segmentation percentages. Industry reports and financial databases are key sources for this approach.
BottomUp Approach: Aggregate sales data or unit shipments from all known market participants. This might require gathering data from company reports, industry associations, and sales channels.
Combining Approaches: Validate the market size estimates by comparing the results from both approaches. Discrepancies can highlight areas requiring further investigation.

Calculating the CAGR for the Market

The Compound Annual Growth Rate (CAGR) is a useful measure to understand market growth over time:
Historical Sales Data: Gather historical sales or market size data over a defined period. Public company filings, industry reports, and government databases can be sources for this data.
CAGR Formula: Apply the CAGR formula \[CAGR = (EV/BV)^{1/n} 1\], where EV is the end value, BV is the beginning value, and n is the number of periods.
Segment and Overall Market CAGR: Calculate CAGR for both the overall market and individual segments to understand growth patterns.

Sources for Secondary or Desk Research

Identifying the right sources is crucial for accurate desk research:
Industry and Market Research Reports: Sources like IBISWorld, Statista, and Frost & Sullivan offer comprehensive industry reports.
Government and International Organizations: Websites of the U.S. Census Bureau, World Bank, and OECD provide economic and industry specific data.
Academic Journals: Platforms like Google Scholar and JSTOR can offer peer reviewed articles on market trends and consumer behavior.
News Archives and Trade Publications: Stay informed on industry developments through sources like Bloomberg, Reuters, and specific trade journals relevant to the market in question.
Each of these steps requires careful consideration and a systematic approach to ensure that the market research report is robust, insightful, and actionable.

Companion Diagnostics Market

Base Year Value ()

CAGR ()

Forecast Year Value ()

Historical Data Period

Largest Region

Forecast Period

Instant access to hundreds of data points and trends

Companion Diagnostics Market Overview

Frequently Asked Questions

• What is the worth of companion diagnostics market?

• What are some of the market's driving forces?

• Which are the top companies to hold the market share in companion diagnostics market?

• Which is the largest regional market for companion diagnostics market?

Companion Diagnostics Market Segment Analysis

Companion Diagnostics Market Players

Who Should Buy? Or Key stakeholders

Companion Diagnostics Market Regional Analysis

Key Market Segments: Companion Diagnostics Market

Exactitude Consultancy Core Companion Diagnostics Services Key Objectives:

Key Question Answered

LIST OF TABLES

LIST OF FIGURES

DOWNLOAD FREE SAMPLE REPORT

License Type

Get Sample to Email

SPEAK WITH OUR ANALYST

WANT TO CUSTOMIZE THE REPORT?

Our Clients Speak

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

Why choose us

In-Depth Database

Recognised Publishing Sources

Customer Support

Safe & Secure

Talk to Expert

+1 (704) 266-3234

Send an Email

Contact us

Quick Links

We accept